Related Experiment Videos
Ifosfamide-induced Fanconi syndrome
1Department of Internal Medicine, University of Illinois at Urbana-Champaign, USA.
The Annals of Pharmacotherapy
|June 1, 1995
Summary
Ifosfamide chemotherapy can cause Fanconi syndrome, a kidney tubule disorder, in adults, even months after treatment. Close monitoring of renal function is crucial for early detection and management of this adverse effect.
Area of Science:
- Nephrology
- Oncology
- Pharmacology
Background:
- Ifosfamide is a chemotherapy agent used to treat various cancers.
- While hemorrhagic cystitis is a known side effect, renal toxicity is also a concern.
- Fanconi syndrome, a generalized proximal tubule dysfunction, is a rare but serious complication.
Observation:
- A 20-year-old male treated for osteosarcoma developed polyuria, polydipsia, and ankle pain three months post-chemotherapy.
- Laboratory tests revealed electrolyte imbalances (hypophosphatemia, hypokalemia, hypocalcemia, bicarbonate wasting) and impaired renal function (elevated BUN and creatinine).
- Increased urinary excretion of phosphate, potassium, calcium, and protein was noted.
Findings:
- The patient was diagnosed with Fanconi syndrome and osteomalacia, likely induced by ifosfamide.
- Treatment with oral supplements (potassium, sodium, calcium, citrate) and calcitriol corrected the electrolyte abnormalities.
- This case highlights the potential for delayed onset of renal tubular dysfunction.
Implications:
- Adult patients receiving ifosfamide require vigilant renal function monitoring.
- Fanconi syndrome and renal failure should be considered in the differential diagnosis of renal abnormalities post-ifosfamide therapy.
- Early detection and management of ifosfamide-induced nephrotoxicity are essential for patient outcomes.